Associate Scientist II, RNAi Discovery

* Design, synthesis, purification, and analysis of chemically modified oligonucleotides.
* Improve upon and/or develop new synthetic methods and processes to expand the current capabilities.
* Utilize a various range of RNA/DNA synthesizers to perform state of the art solid-phase oligoncueltide synthesis at various scales.
* Utilize analytical instrumentation such as UV-Vis spectroscopy, HPLC, and/or LC-MS for the analysis of both crude and purified synthetic products. Effectively troubleshoot synthetic/process issues and independently find solutions.
* Improve upon and/or develop new methods and automation for the downstream processing of synthetic oligonucleotides and their subsequent analysis/purification and annealing into siRNA duplexes.
* Analyze, interpret, and organize analytical data to present to team members.

Qualifications

* Bachelor's in Chemistry, Biochemistry, or a related field.
* 0-3 years of work experience in an industrial or academic lab setting
* Experience with solid-phase synthesis (oligonucleotides, peptides, etc) is preferred but a background in organic chemistry is sufficient. Conjugation experience (i.e "click" chemistry) is a plus.
* Experience with instrumentation such as analytical and prep HPLC, LC-MS, UV-Vis spectrometry, etc. is required.
* Good understanding of chromatography and experience in developing methods (IEX/RP HPLC, LC-MS) is a plus.
* Ability to function within a highly interdisciplinary environment is a must.
* Excellent written and oral communication skills, good organization skills, the ability to multitask, and the ability to work within a team and/or independently are required.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.